CardioExchange Archive

CardioExchange, an NEJM practice community for medical professionals dedicated to improving cardiac patient care, was active from 2009 to 2015. CardioExchange fostered discussion between clinicians from across the globe.

October 6th, 2011

J&J Pleads Guilty, Pays $85 Million to Settle Natrecor Case

The U.S. Department of Justice announced that Johnson & Johnson has pleaded guilty to a misdemeanor and has agreed to pay an $85 million criminal fine to settle charges about the company’s marketing of Natrecor (nesiritide) for off-label use.

The government said that Scios, the J&J subsidiary that marketed the drug, “admitted that it intended Natrecor to be used off-label for infusing chronic (non-acute) CHF patients on a scheduled, serial basis and that it understood that this was not an approved use of the drug.”

Categories: Heart Failure
Tags: ,


You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Comments are closed.